Anders Jacobsen Skanderup
Overview
Explore the profile of Anders Jacobsen Skanderup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
789
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ng M, Chen S, Ong W, Balachander A, Seet A, Yeong J, et al.
Int J Cancer
. 2022 Apr;
151(3):435-449.
PMID: 35415893
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and debilitating disease with limited therapeutic options. The aim of this clinical study was to evaluate the safety, efficacy and pharmacokinetics of...
12.
Zhai W, Lai H, Kaya N, Chen J, Yang H, Lu B, et al.
Natl Sci Rev
. 2022 Apr;
9(3):nwab192.
PMID: 35382356
Intra-tumor heterogeneity (ITH) is a key challenge in cancer treatment, but previous studies have focused mainly on the genomic alterations without exploring phenotypic (transcriptomic and immune) heterogeneity. Using one of...
13.
Oner M, Chen J, Revkov E, James A, Heng S, Kaya A, et al.
Patterns (N Y)
. 2022 Feb;
3(2):100399.
PMID: 35199060
Tumor purity is the percentage of cancer cells within a tissue section. Pathologists estimate tumor purity to select samples for genomic analysis by manually reading hematoxylin-eosin (H&E)-stained slides, which is...
14.
15.
Sheng T, Ho S, Ooi W, Xu C, Xing M, Padmanabhan N, et al.
Genome Med
. 2021 Oct;
13(1):158.
PMID: 34635154
Background: Enhancers are distal cis-regulatory elements required for cell-specific gene expression and cell fate determination. In cancer, enhancer variation has been proposed as a major cause of inter-patient heterogeneity-however, most...
16.
Sundar R, Huang K, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, et al.
Gut
. 2021 Aug;
71(7):1277-1288.
PMID: 34433583
Objectives: Epigenomic alterations in cancer interact with the immune microenvironment to dictate tumour evolution and therapeutic response. We aimed to study the regulation of the tumour immune microenvironment through epigenetic...
17.
Seet A, Tan A, Tan T, Ng M, Tai D, Lam J, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250396
Purpose: Precision oncology has transformed the management of advanced cancers through implementation of advanced molecular profiling technologies to identify increasingly defined subsets of patients and match them to appropriate therapy....
18.
Guo Y, Chang M, Skanderup A
NPJ Genom Med
. 2020 Jun;
5:26.
PMID: 32550006
Recurrence and clustering of somatic mutations (hotspots) in cancer genomes may indicate positive selection and involvement in tumorigenesis. MutSpot performs genome-wide inference of mutation hotspots in non-coding and regulatory DNA...
19.
Xing M, Ooi W, Tan J, Qamra A, Lee P, Li Z, et al.
J Clin Invest
. 2020 May;
130(6):3005-3020.
PMID: 32364535
Transcriptional reactivation of telomerase catalytic subunit (TERT) is a frequent hallmark of cancer, occurring in 90% of human malignancies. However, specific mechanisms driving TERT reactivation remain obscure for many tumor...
20.
Huang W, Guo Y, Chang M, Skanderup A
Methods Mol Biol
. 2020 Mar;
2120:37-46.
PMID: 32124310
Identification of somatic mutations in tumor tissue is challenged by both technical artifacts, diverse somatic mutational processes, and genetic heterogeneity in the tumors. Indeed, recent independent benchmark studies have revealed...